Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma

Madelon Q. Wentink; Henk M.W. Verheul; Sumanta K. Pal; Saby George; Johannes Voortman; Pongwut Danchaivijitr; Remi Adelaiye; Diane Poslinski; Adrienne Groman; Alan Hutson; Roberto Pili

doi:10.1016/j.clgc.2017.07.004

journal article Feb 01, 2018

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma

Madelon Q. Wentink Henk M.W. Verheul

Sumanta K. Pal Saby George

Johannes Voortman Pongwut Danchaivijitr Remi Adelaiye Diane Poslinski Adrienne Groman Alan Hutson Roberto Pili

Clinical Genitourinary Cancer Vol. 16 No. 1 pp. e1-e9 · Elsevier BV

View at Publisher Save 10.1016/j.clgc.2017.07.004

Topics

No keywords indexed for this article. Browse by subject →

References

27

[1]

Takahashi "Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis" Cancer Res (1994)

[2]

Gnarra "Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene" Proc Natl Acad Sci U S A (1996) 10.1073/pnas.93.20.10589

[3]

Motzer "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma" N Engl J Med (2007) 10.1056/nejmoa065044

[4]

Klerk "The effect of low molecular weight heparin on survival in patients with advanced malignancy" J Clin Oncol (2005) 10.1200/jco.2005.03.134

[5]

Barni "The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?" Blood (2014) 10.1182/blood-2014-03-561761

[6]

Battinelli "Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response" Blood (2014) 10.1182/blood-2013-02-485011

[7]

Nakasaki "Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer" Am J Hematol (2002) 10.1002/ajh.10061

[8]

Verheul "Platelet: transporter of vascular endothelial growth factor" Clin Cancer Res (1997)

[9]

Battinelli "Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis" Blood (2011) 10.1182/blood-2011-02-334524

[10]

Verheul "Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition" Nat Rev Cancer (2007) 10.1038/nrc2152

[11]

Ma "In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy" Cancer Res (2005) 10.1158/0008-5472.can-04-3156

[12]

Verheul "Platelets take up the monoclonal antibody bevacizumab" Clin Cancer Res (2007) 10.1158/1078-0432.ccr-07-0847

[13]

Zangari "Thrombotic events in patients with cancer receiving antiangiogenesis agents" J Clin Oncol (2009) 10.1200/jco.2009.22.3875

[14]

Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials

John Bryant, Roger Day

Biometrics 1995 10.2307/2533268

[15]

Heng "Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study" J Clin Oncol (2009) 10.1200/jco.2008.21.4809

[16]

Je "Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials" Lancet Oncol (2009) 10.1016/s1470-2045(09)70222-0

[17]

Norden "Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients" J Neurooncol (2012) 10.1007/s11060-011-0642-1

[18]

Scappaticci "Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab" J Natl Cancer Inst (2007) 10.1093/jnci/djm086

[19]

Stobe "Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency" Int J Clin Pharmacol Ther (2006) 10.5414/cpp44455

[20]

Schmid "Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency" J Thromb Haemost (2009) 10.1111/j.1538-7836.2009.03556.x

[21]

Atiq "A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency" Eur J Clin Pharmacol (2015) 10.1007/s00228-015-1880-5

[22]

Zhang J Biol Chem (2006) 10.1074/jbc.m604905200

[23]

DePrimo "Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins" J Transl Med (2007) 10.1186/1479-5876-5-32

[24]

Kontovinis "Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers" BMC Cancer (2009) 10.1186/1471-2407-9-82

[25]

Zurita "A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma" Ann Oncol (2012) 10.1093/annonc/mdr047

[26]

Harmon "Circulating proteins as potential biomarkers of sunitinib and interferon-alpha efficacy in treatment-naive patients with metastatic renal cell carcinoma" Cancer Chemother Pharmacol (2014) 10.1007/s00280-013-2333-4

[27]

Gruenwald "Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib" BMC Cancer (2010) 10.1186/1471-2407-10-695

Metrics

10

Citations

27

References

Details

Published: Feb 01, 2018
Vol/Issue: 16(1)
Pages: e1-e9
License: View

Authors

16Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

8Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

J

Johannes Voortman

P

Pongwut Danchaivijitr

Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York, USA

R

Roberto Pili

1Gentourinary Program, Simon Cancer Center, Indiana University, Indianapolis, Indiana.; 7Department of Urology, Indiana University, Indianapolis, Indiana.

Funding

American Society of Clinical Oncology

Pfizer

Association of Schools and Colleges of Optometry

Cite This Article

Madelon Q. Wentink, Henk M.W. Verheul, Sumanta K. Pal, et al. (2018). Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer, 16(1), e1-e9. https://doi.org/10.1016/j.clgc.2017.07.004

Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma

You May Also Like